Close Menu

Biocept

The trial aims to demonstrate the utility of Biocept's Target Selector PD-L1 assay in patients diagnosed with non-small cell lung cancer.

The company had $1.1 million in revenue during the quarter, a 10 percent increase year over year despite what the firm said was a 15 to 20 percent sales reduction due to recent hurricanes.

The Target Selector technology is designed to analyze both circulating tumor cell and circulating tumor DNA biomarkers from a blood sample.

Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.

The liquid biopsy firm ran 1,405 tests in the second quarter and made progress on collecting payment from third-party health plans.

Biocept is also working with the buyer — a Hong Kong-based investment group — to explore strategic opportunities in China.

The company's total revenues were $1.7 million, including $897,000 in commercial testing revenue. Its test volume was up 38 percent.

Pages